AI in drug discovery Innophore’s AI guided Catalophore platform enables rapid protein and enzyme candidate identification and optimization, presenting a sales opportunity to biotech and pharma customers seeking to accelerate R&D timelines and increase hit rates in drug discovery and repurposing.

Sustainable production The platform supports sustainable production of high-value compounds by enabling discovery of enzymes and pathways optimized for greener manufacturing, which can be pitched to sustainability-focused biopharma, flavor and fragrance, and industrial biotech clients.

high-profile references With current global customers and partnerships highlighted (e.g., Henkel, Continental, Merck; collaboration with NVIDIA), Innophore can leverage credibility to engage new enterprise clients seeking proven AI-driven discovery platforms and validated case studies.

AI safety screening Recent announcements of CavitOmiX and AI-based drug safety screening, including a collaboration with NVIDIA, present a tangible cross-sell or expansion path for customers needing integrated safety assessment within drug development pipelines.

Global research momentum The expanding protein structure databases and DeepMind/ESM Atlas context create demand for advanced Catalophore-based search capabilities, offering opportunities to partner with large research organizations and CROs looking to augment their bioinformatics toolkits.